ArticleCancer immunology research2016
Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
Article in Cancer immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma.Expert opinion on investigational drugs · 2026Review
- Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200.Frontiers in oncology · 2026Review
- Canine Multicentric Lymphoma: Diagnostic, Treatment, and Prognostic Insights.Animals : an open access journal from MDPI · 2025Review
- Characterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies.PloS one · 2025Article
- Silencing of SIRPα enhances the antitumor efficacy of CAR-M in solid tumors.Cellular & molecular immunology · 2024Article
- Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy.Genes & diseases · 2024Review
- Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs.Frontiers in immunology · 2023Review
- Racing CARs to veterinary immuno-oncology.Frontiers in veterinary science · 2023Review
- Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY.Scientific reports · 2022Article
- A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells.Frontiers in oncology · 2022Article
- Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy.Kidney diseases (Basel, Switzerland) · 2022Review
- Comparative Expression Analysis of Innate Immune Markers and Phagocytic Activity in Peripheral Blood of Dogs with Mammary Tumors.Animals : an open access journal from MDPI · 2021Article
- Beyond tradition and convention: benefits of non-traditional model organisms in cancer research.Cancer metastasis reviews · 2021Review
- Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer.Journal for immunotherapy of cancer · 2021Review
- Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma.Frontiers in veterinary science · 2021Review
- Current Advances inFrontiers in pharmacology · 2021Review
- Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade.Melanoma research · 2020Article
- Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes.Veterinary pathology · 2020Article
- Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies.OncoTargets and therapy · 2020Review
- Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Funding
Abstract
Cancer immunotherapies hold much promise, but their potential in veterinary settings has not yet been fully appreciated. Canine lymphomas are among the most common tumors of dogs and bear remarkable similarity to human disease. In this study, we examined the combination of CD47 blockade with anti-CD20 passive immunotherapy for canine lymphoma. The CD47/SIRPα axis is an immune checkpoint that regulates macrophage activation. In humans, CD47 is expressed on cancer cells and enables evasion from phagocytosis. CD47-blocking therapies are now under investigation in clinical trials for a variety of human cancers. We found the canine CD47/SIRPα axis to be conserved biochemically and functionally. We identified high-affinity SIRPα variants that antagonize canine CD47 and stimulate phagocytosis of canine cancer cells in vitro When tested as Fc fusion proteins, these therapeutic agents exhibited single-agent efficacy in a mouse xenograft model of canine lymphoma. As robust synergy between CD47 blockade and tumor-specific antibodies has been demonstrated for human cancer, we evaluated the combination of CD47 blockade with 1E4-cIgGB, a canine-specific antibody to CD20. 1E4-cIgGB could elicit a therapeutic response against canine lymphoma in vivo as a single agent. However, augmented responses were observed when combined with CD47-blocking therapies, resulting in synergy in vitro and in vivo and eliciting cures in 100% of mice bearing canine lymphoma. Our findings support further testing of CD47-blocking therapies alone and in combination with CD20 antibodies in the veterinary setting. Cancer Immunol Res; 4(12); 1072-87. ©2016 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.